A cohort study in patients with StageIIIB/IVnon-small cell lung cancer, who had treated as 1st-line Conbination therapy of Carboplatin/Paclitaxel/Bavacizumab, and 2nd-line by Erlotinib

A cohort study in patients with StageIIIB/IVnon-small cell lung cancer, who had treated as 1st-line Conbination therapy of Carboplatin/Paclitaxel/Bavacizumab, and 2nd-line by Erlotinib - A cohort study in patients with StageIIIB/IVnon-small cell lung cancer, who had treated as 1st-line Conbination therapy of Carboplatin/Paclitaxel/Bavacizumab, and 2nd-line by Erlotinib

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000006079

Enrollment

Registered

2011-07-30

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)histologically or cytologically confirmed non-squamous non-small-cell lung cancer 2) stage IIIB/IV or postoperative recurrence patients 3)chemotheraoy naive patients 4)Patients providing written informed consent

Exclusion criteria

Exclusion criteria: 1)Inappropriate patients for this study judged by the physicians

Design outcomes

Primary

Measure	Time frame
Time to Treatment Failure	—

Secondary

Measure	Time frame
2nd PFS, Adverse events, Overall survival,	—

Countries

Japan

Outcome results